CCA Summit Live from ESMO GI 2022

Angela Lamarca, MD, PhD, MSc

CCA Summit Live from ESMO GI 2022

ESMO GI Highlights

Videos — July 12, 2022

Featuring:

Angela Lamarca, MD, PhD, MSc

Consultant (FEA) in Medical Oncology
HPB-NET–Gastrointestinal Tumors Group, Department of Oncology
Fundación Jiménez Díaz University Hospital
Autonomous University of Madrid
Madrid, Spain

Angela Lamarca, MD, PhD, MSc, Consultant (FEA) in Medical Oncology presents an overview of key abstracts on cholangiocarcinoma (CCA) presented at the 2022 annual meeting of the ESMO World Congress on Gastrointestinal Cancer (ESMO GI 2022). Dr Lamarca also provides her perspective on the impact of the data on the management of patients with CCA.

ESMO GI Highlights

September 2022, Vol 3, No 3

First-line treatment options are limited to gemcitabine/cisplatin (GemCis) for patients with advanced cholangiocarcinoma (CCA).

Pemigatinib for Metastatic CCA: Final Results from FIGHT-202

ESMO GI Highlights

September 2022, Vol 3, No 3

Pemigatinib is an oral, potent, selective fibroblast growth factor receptor (FGFR)1-3 inhibitor that is currently approved for the treatment of adults with previously treated, unresectable, locally advanced/metastatic cholangiocarcinoma (CCA) bearing an FGFR2 fusion or other rearrangement based on the FIGHT-202 trial.

Outcomes by Primary Tumor Location in Patients with Advanced BTCs: Subanalysis of Phase 3 TOPAZ-1

ESMO GI Highlights

September 2022, Vol 3, No 3

Results of the randomized, double-blind, global, phase 3 TOPAZ-1 trial (NCT03875235) demonstrated that the first-line chemoimmunotherapy regimen of the PD-L1 inhibitor durvalumab plus gemcitabine/cisplatin (GemCis; median follow-up, 13.7 months) significantly improved overall survival (OS) versus placebo plus GemCis (median follow-up, 12.6 months).¹

Outcomes by Disease Status in Patients with Advanced BTCs: Subanalysis of Phase 3 TOPAZ-1

ESMO GI Highlights

September 2022, Vol 3, No 3

Tumor Markers in Patients with Advanced BTCs Treated with Second-Line ASC Alone or with FOLFOX: The ABC-06 Trial

ESMO GI Highlights

September 2022, Vol 3, No 3

The randomized, open-label, multicenter, phase 3 ABC-06 trial established folinic acid/fluorouracil/oxaliplatin chemotherapy (FOLFOX) plus active symptom control (ASC) as the standard-of-care second-line treatment in patients with advanced biliary tract cancers (BTCs).¹

QOL Assessment in BTCs: A Systematic Review of Phase 2 and 3 Clinical Trials

ESMO GI Highlights

September 2022, Vol 3, No 3

Although the clinical relevance of quality of life (QOL) is increasingly being acknowledged, it is rarely included as a clinical study end point in biliary tract cancers (BTCs).

An Exciting Time for Cholangiocarcinoma Therapy

By Jesús Bañales, PhD; Antoine Hollebecque, MD; Milind M. Javle, MD; Angela Lamarca, MD, PhD, MSc

Conversations on Cholangiocarcinoma

Videos

Understanding more about the molecular biology of cholangiocarcinoma will improve its treatment

The Future of Chemotherapy in CCA

By Juan W. Valle, MB ChB, MSc, FRCP; Angela Lamarca, MD, PhD, MSc

Highlights from the 3rd Annual CCA Summit

Videos

Drs Juan Valle and Angela Lamarca discuss clinical studies being conducted to improve the use of chemotherapy in CCA by exploring molecular biomarkers that could help patient selection for optimal response to certain chemotherapy regimens.

A View to the Future of Cholangiocarcinoma Therapy

By Jesús Bañales, PhD; Antoine Hollebecque, MD; Milind M. Javle, MD; Angela Lamarca, MD, PhD, MSc

Conversations on Cholangiocarcinoma

Videos

Clinical studies are required to define role of targeted therapy in cholangiocarcinoma

Mechanisms of Resistance to FGFR Inhibitors

By Jesús Bañales, PhD; Antoine Hollebecque, MD; Milind M. Javle, MD; Angela Lamarca, MD, PhD, MSc

Conversations on Cholangiocarcinoma

Videos

Drs Javle, Bañales, and Hollebecque discuss the innate and acquired resistance pathways to FGFR inhibitors in cholangiocarcinoma and how these pathways can have important effects on clinical outcomes. They also look ahead to ongoing clinical trials evaluating next-generation FGFR inhibitors that may be able to overcome resistance mechanisms and improve progression-free and overall survival in cholangiocarcinoma.

CCA Summit Live from ESMO GI 2022

Featuring:

Subscribe Today!

I'd like to receive:

Stay In The Know

CCA Summit Live from ESMO GI 2022

Featuring:

Related Items

Subscribe Today!

I'd like to receive:

Stay In The Know